Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genevant Sciences GmbH maintains a distributed prosecution profile within the Biotechnology & Pharmaceuticals technology area. The company currently has 4 pending office actions, each of which is being processed in 1 of 4 distinct art units. This distribution indicates that the company's biotechnology innovations are being reviewed by several different specialized groups within the USPTO. The use of 4 distinct art units suggests that the portfolio's technical scope is broad and covers multiple sub-specialties.
The examination of these applications is split among 4 distinct examiners, ensuring a variety of perspectives on the company's filings. ARNOLD, ERNST V is the busiest examiner, although he is only responsible for 1 busiest examiner pending office action. This means that each of the 4 pending office actions is being handled by a different individual, creating a decentralized examination environment. This structure requires practitioners to adapt to 4 different examination styles and sets of art unit expectations simultaneously.
Managing 4 pending office actions across 4 distinct art units requires a coordinated effort to ensure consistency. Since no single examiner handles more than 1 busiest examiner pending action, there is no concentration of workload that would allow for a unified negotiation strategy. Instead, each of the 4 distinct examiners must be addressed individually within their respective biotechnology sub-specialties. This distribution within the Biotechnology & Pharmaceuticals sector provides the company with a broad exposure to various USPTO examination practices.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
| HASAN, KHALEDA B | 1 | 59.3% | +49.0% |
| MARVICH, MARIA | 1 | 55.0% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17771421 | ORNITHINE TRANSCARBAMYLASE (OTC) CONSTRUCTS AND METHODS OF USING THE SAME | MARVICH, MARIA | 63d |
| 18015398 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | HASAN, KHALEDA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17771421 | ORNITHINE TRANSCARBAMYLASE (OTC) CONSTRUCTS AND METHODS OF USING THE SAME | MARVICH, MARIA | 63d |
| 18832438 | POLY(ALKYLOXAZOLINE)-LIPID CONJUGATES AND LIPID PARTICLES CONTAINING SAME | ARNOLD, ERNST V | — |
| 18586033 | BLOCK COPOLYMERS | KELLY, ROBERT M | — |
| 18015398 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | HASAN, KHALEDA B | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1638 | 1 |
| 1636 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18832438 | POLY(ALKYLOXAZOLINE)-LIPID CONJUGATES AND LIPID PARTICLES CONTAINING SAME | ARNOLD, ERNST V | 1613 | §103§112DP | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18586033 | BLOCK COPOLYMERS | KELLY, ROBERT M | 1638 | §112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18015398 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | HASAN, KHALEDA B | 1636 | §102§103§112 | Non-Final OA | — | Pending | Jan 10, 2023 |
| 17771421 | ORNITHINE TRANSCARBAMYLASE (OTC) CONSTRUCTS AND METHODS OF USING THE SAME | MARVICH, MARIA | 1634 | §103§112Other | Final Rejection | 63d | Pending | Apr 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenevant Sciences GmbH has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Ernst V Arnold has the most, with 1 of Genevant Sciences GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
